Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 185   

Articles published

PFE 29.26 -0.13 (-0.44%)
price chart
Is It Time to Buy Pfizer Inc.'s Stock?
Since the recession ended, shareholders in Pfizer (NYSE: PFE ) , the world's largest pharmaceutical company by revenue, have seen their shares more than double.
Related articles »  
SunTrust Sees Further Pfizer Inc. Bid For AstraZeneca PLC 'Highly Likely'
Pfizer Inc. (NYSE: PFE) is likely to boost its offer for British drug maker AstraZeneca PLC (NYSE: AZN) to $96.28 a share, an analyst said Tuesday.
Related articles »  
3 Reasons Pfizer Inc.'s Stock Could Fall
Pfizer (NYSE: PFE ) may be the largest pharmaceutical company in the world, but size isn't everything when it comes to developing and selling drugs.
Related articles »  
3 Reasons Pfizer Inc.'s Stock Could Rise
Pfizer (NYSE: PFE ) , arguably the preeminent pharmaceutical company in the world, continues to pump out billions in free cash flow annually, deliver delectable gross margins, and pay out an annual dividend that puts the S&P 500 average yield of 2% to ...
Related articles »  
Pfizer Inc. (PFE), General Electric Company (GE) and Eaton Corp plc (ETN): Top ...
According to the 13F form filed by Levin Capital Strategies, managed by John A. Levin, Pfizer Inc. (NYSE:PFE), General Electric Company (NYSE:GE) and Eaton Corp plc (NYSE:ETN) are among the top holdings of the fund.
AstraZeneca rises as investors bet on revival of Pfizer deal
According to reports July 29, 2014, Pfizer Inc.. the second-largest U.S. pharmaceutical maker, posted a 79 percent drop in second quarter profits, but beat analyst expectations.
5 Things Pfizer Inc.'s Management Wants You to Know
For the quarter, Pfizer reported that revenue slipped 2%, or $200 million, to $12.77 billion. Profits were also a mixed tale with Pfizer's adjusted income dipping 6% and its adjusted EPS rising 4%. The company also lowered its full-year revenue ...
Pfizer Inc. (PFE): Trouble Ahead For The Stock  ETF Daily News
Intel Corporation (NASDAQ:INTC), Pfizer Inc. (NYSE:PFE), Microsoft ...  US Trade Media
Related articles »  
Pfizer: Prescription For A Strong Dividend Yield (PFE)
Pfizer (NYSE:PFE) looks like a good buy due to its (1) strong balance sheet, (2) low valuation, and (3) attractive dividend yield.
AstraZeneca now tougher target for Pfizer
Pfizer Inc. isn't giving up on striking an overseas takeover to cut its tax rate and gain a new pipeline of drugs, even as the potential cost of acquiring AstraZeneca Plc rises.
AstraZeneca Is Tougher Target for Possible New Pfizer Bid  Bloomberg
AstraZeneca is tougher Pfizer target as possible new bid looms  Livemint
Related articles »  
Merck Collaborates With Pfizer Again For Its PD-1 Immunotherapy
Pfizer Inc. (PFE) and Merck & Co., Inc. (MRK) announced yesterday that they have partnered to conduct trials investigating the combined efficacy of the former's lung-cancer drug, Xalkori, along with the latter's experimental drug, Pembrolizumab ...
Pfizer to test Xalkori lung cancer drug with Merck immunotherapy  Reuters UK
Related articles »